

Predictors of *Clostridium difficile* colitis infections in hospitals

R. RICCIARDI^{1,2,3*}, K. HARRIMAN⁴, N. N. BAXTER^{5,6}, L. K. HARTMAN⁷,
R. J. TOWN⁷ AND B. A. VIRNIG^{1,7}

¹ Department of Surgery, University of Minnesota, Minneapolis, MN, USA

² Department of Colon and Rectal Surgery, Lahey Clinic, Burlington, MA, USA

³ Institute for Clinical Research and Health Policy Studies, Tufts University, Boston, MA, USA

⁴ Minnesota Department of Public Health, St. Paul, MN, USA

⁵ Department of Surgery, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada

⁶ Department of Health Research, Policy, and Evaluation, University of Toronto, Toronto, ON, Canada

⁷ Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis, MN, USA

(Accepted 11 July 2007; first published online 9 August 2007)

SUMMARY

Hospital-level predictors of high rates of 'Clostridium difficile-associated disease' (CDAD) were evaluated in over 2300 hospitals across California, Arizona, and Minnesota. American Hospital Association data were used to determine hospital characteristics associated with high rates of CDAD. Significant correlations were found between hospital rates of CDAD, common infections and other identified pathogens. Hospitals in urban areas had higher average rates of CDAD; yet, irrespective of geographic location, hospital rates of CDAD were associated with other infections. In addition, hospitals with 'high CDAD' rates had slower turnover of beds and were more likely to offer transplant services. These results reveal large differences in rates of CDAD across regions. Hospitals with high rates of CDAD have high rates of other common infections, suggesting a need for broad infection control policies.

INTRODUCTION

Clostridium difficile-associated disease (CDAD) is a common cause of nosocomial diarrhoea and is associated with substantial morbidity and mortality [1]. Recent population-based data reveal an increase in the prevalence and severity of CDAD in the United States [1, 2]. Changes in the epidemiology of *C. difficile* may be secondary to the emergence of epidemic strains in many areas of the United States and Canada [3, 4]. In addition, others have demonstrated

reduced efficacy of usual medical therapies, such as metronidazole and vancomycin, although resistance to these agents has not been demonstrated [5, 6]. A number of authors have sought to define patient-level risk factors that predispose patients to CDAD. Most such analyses have examined patient demographics [7–9], comorbid conditions [10–12], clinical variables [7, 8], and antibiotic treatment characteristics [7, 8, 13]. Patient-level risk factors have been used to help develop treatment algorithms [14], and may also be useful in developing prevention and control measures.

Most cases of CDAD are transmitted while patients are in the hospital, often through contamination of the hands of hospital personnel caring for them [9].

* Author for correspondence: R. Ricciardi, M.D., M.P.H., Department of Colon and Rectal Surgery, Lahey Clinic, 41 Mall Road, Burlington, MA 01805, USA.
(Email: rocco.ricciardi@lahey.org)

A recent county-level evaluation in Sweden revealed that hospital-acquired CDAD is 1300 times more common than community-acquired infections [15]. Thus, effective prevention and control measures are needed to reduce acquisition of CDAD. An evaluation of hospital-level characteristics may be more useful than a focus solely on patient-level factors. For this reason, an analysis of hospitals with the highest proportion of CDAD and their risk factors is needed. In this study, high rates of CDAD were compared to hospital admission, personnel, and service characteristics for hospitals with high rates of CDAD and compared to those with fewer CDAD cases.

METHODS

Data sources

Hospital in-patient discharge data, which contain greater than 95% of all discharge abstracts of non-government in-patient facilities, were obtained for California, Arizona, and Minnesota. These data provided information on patient demographics, socioeconomic factors, admission profiles, hospital profiles, state codes, discharge diagnoses, procedure codes, total charges, and vital status at hospital discharge. Data use agreements are held by the respective state data collectors, so all study protocols were considered exempt by the University of Minnesota institutional review board.

The American Hospital Association (AHA) Annual Survey of Hospitals database for the time period January 2000–December 2003 was obtained in order to determine hospital structural and service lines associated with high rates of CDAD. The AHA database contains hospital-specific information on over 6000 hospitals and over 450 health-care systems, including 700 data elements [16]. The purpose of the AHA database is to generate a comprehensive and inclusive overview of hospitals while permitting the tracking of hospital performance over time. AHA data have been extensively used to study hospital-based outcomes [17], hospital policies [18], and reimbursement [19].

Hospital infection rates

Diagnostic codes from the International Classification of Diseases (ICD-9) were used to identify all patients who were discharged with a diagnosis of

C. difficile-pseudomembranous colitis (ICD-9 code 8.45) [1, 2] from January 2000 to December 2003. Patients with either a primary or secondary diagnosis of CDAD were summed to calculate yearly hospital rates/1000 discharges. Hospitals were divided into two groups: Those whose CDAD rates were in the 90th percentile of all hospitals studied ('high CDAD' hospitals) and the remaining hospitals. Psychiatric facilities, chemical dependency facilities, and hospitals with incomplete information were excluded.

To test the association between CDAD and other infections, previously published methods of identifying common infections as well as an estimate of other bacterial infections were used. First, the proportion of patients with discharge diagnoses of other commonly treated infections, i.e. pneumonia [20], urinary tract infections [21], endocarditis [22], cellulitis [23], bloodstream infections [24], and osteomyelitis [25] for the entire cohort, for each state, and for each hospital was determined. Next, the proportion of admissions for each of these infections to the total of individual hospital discharges was calculated. In addition, the rate of discharges for other common bacterial infections (*Escherichia coli*, *Pseudomonas*, *Streptococcus*, and *Staphylococcus*) was calculated for the entire cohort, for each state, and for each hospital.

AHA variables

Survey results from the AHA files were used to include the time period from January 2000 to December 2003. The hypothesis tested was that hospitals with high rates of CDAD can be characterized by particular hospital characteristics, specifically hospital structural, personnel, and service-line data. These characteristics were chosen because of the ease of obtaining these variables and because high institutional rates of CDAD have been described in particular types of facilities [26, 27] and these files were merged with the administrative hospital data described previously. First, hospital structural characteristics and service lines were evaluated. Staffing characteristics were determined in terms of the number of full-time-equivalent medical doctors, registered nurses, and medical residents as well as other hospital factors such as distinction as a critical access hospital for hospitals with <25 beds, presence of an emergency department, and total number of annual surgical procedures.

Statistical analysis

A correlation analysis was used to assess associations between the rates of CDAD and the rates of other bacterial infections. Similarly, the rates of CDAD were compared with rates of six common infections (pneumonia, urinary tract infections, endocarditis, cellulitis, bloodstream infections, and osteomyelitis). The mean rate of these infections and of four other bacterial species (*E. coli*, *Pseudomonas*, *Streptococcus*, and *Staphylococcus*) was determined for 'high CDAD' hospitals and all other hospitals. χ^2 tests were used to compare categorical variables (AHA data) and analysis of variance for continuous variables (mean rates of infection).

A logistic regression model was constructed to evaluate the relationship between 'high CDAD' hospitals in the 90th percentile of CDAD infections (categorical variable) and AHA characteristics. For this analysis, variables from the AHA files and the hospital location were included, while excluding infection variables because of the strong correlations between CDAD, other bacterial pathogens, and other common infections. The AHA categorical variables included were: characterization as a trauma facility, critical access hospital, patient burn beds, residents in training, haemodialysis, neurology, orthopaedic, palliative care, transplant, emergency department, cardiac intensive care, and rehabilitation services. AHA continuous variables were number of full-time medical doctors, registered nurses, hospital beds and surgical procedures in tertiles. The total annual hospital discharge figure was divided by total hospital beds in order to estimate patient bed turnover by facility. A comparatively high bed turnover ratio indicates a shorter length of stay (variable entered into model as a continuous variable). A similar analysis was performed for 'high CDAD' hospitals for each state.

RESULTS

Cohort characteristics

This analysis reflects the characterization of 20292499 discharges over the 4-year study period. Of these discharges, 80 619 patients had CDAD codes giving a rate of 3.97 CDAD infections/1000 discharges. The rate of CDAD for each metropolitan statistical area is presented in the Figure. Hospitals in the most populous localities had the highest rates of CDAD.




Fig. Mean number (with S.E.M.) of *C. difficile* colitis cases (number of cases/1000 hospitalized patients) by metropolitan statistical area (MSA). Code: MSA 0, non-metropolitan area; MSA 1, <100 000 population; MSA 2, 100 000–250 000 population; MSA 3, 250 000–500 000 population; MSA 4, 500 000–1 000 000 population; MSA 5, 1 000 000–2 500 000 population; MSA 6, >2 500 000 population.

Hospital-level analysis

Hospital characteristics

Data were available for 2363 acute care hospitals in the three states. CDAD was noted in 2075 hospitals (87.8% of the total). The mean hospital rate (\pm S.D.) for CDAD was 6.3 ± 18.5 infections/1000 discharges. The mean hospital rate for the other bacterial infections was greatest for *E. coli* (13.5 ± 9.4 infections/1000 discharges), followed by *Staphylococcus*, *Streptococcus*, and *Pseudomonas* (Table 1). Other infections were noted in the majority of hospitals. Almost all hospitals treated at least one patient with a urinary tract infection (98.9%), pneumonia (98.7%), cellulitis (98.5%), bloodstream infection (97.0%), and osteomyelitis (90.3%); only 71.4% of hospitals treated at least one patient with endocarditis. The mean hospital rate for the other infections was highest for pneumonia (93.0 ± 72.3 cases/1000 discharges), followed by urinary tract infections, cellulitis, bloodstream infections, osteomyelitis, and endocarditis (Table 1).

Hospital characteristics were obtained from the AHA data for the majority of hospitals. The data revealed that the hospitals averaged 176.6 ± 155.2 beds, 5248 ± 5208 annual surgical procedures, and 8270 ± 8533 discharges. A minority of hospitals admitted trauma patients (20.6%), provided transplant services (7.4%), or had beds assigned for burn patients (3.3%). Only 35.7% provided cardiac intensive care services (Tables 2 and 3).

Table 1. *Hospital characteristics (for bacterial isolates and commonly treated infections)*

	Hospital infection rate (per 1000 discharges)
<i>C. difficile</i>	6.3 ± 18.5
<i>E. coli</i>	13.5 ± 9.4
<i>Pseudomonas</i>	4.6 ± 9.0
<i>Staphylococcus</i>	11.5 ± 15.3
<i>Streptococcus</i>	6.5 ± 6.6
Bloodstream	24.9 ± 35.5
Cellulitis	27.5 ± 17.8
Endocarditis	1.0 ± 2.0
Osteomyelitis	5.3 ± 10.4
Pneumonia	93.0 ± 72.3
Urinary tract	72.0 ± 49.4

Values are mean ± s.d.

Table 2. *Hospital characteristics (proportion of hospitals with identified service offering)*

	Proportion of hospitals with service (%)
Emergency department services	71.4
Orthopaedic services	50.0
Cardiac intensive care services	35.7
Neurology services	32.0
Haemodialysis services	27.7
Rehabilitation services	23.6
Trauma hospital	20.6
Palliative care services	19.5
Critical access hospital	10.4
Transplant hospital	7.3
Patient burn beds	3.3

Table 3. *Hospital characteristics (hospital beds, staffing levels, and bed turnover)*

	Mean per hospital
Hospital beds	176.6 ± 155.2
Total surgical procedures	5248 ± 5208
Full-time medical doctors	17.1 ± 71.4
Full-time registered nurses	154.9 ± 197.9
Full-time residents	15.8 ± 67.2
Bed turnover (discharges/bed)	44.2 ± 27.1

Values are mean ± s.d.

Infection correlations

Statistically significant correlations for hospital rates of CDAD and the other bacterial pathogens were noted. The correlation between CDAD and

Pseudomonas was highest, followed by *Staphylococcus*, *Streptococcus*, and *E. coli* (Table 4). Statistically significant correlations were also found between CDAD and bloodstream infections, followed by endocarditis, osteomyelitis, pneumonia, urinary tract infections, and cellulitis (Table 5).

'High CDAD' hospitals and infections

A group of hospitals was identified as having a disproportionately higher rate of CDAD, a plot of CDAD for each facility revealed an inflection point at which the rate of cases increased disproportionately. This inflection point of CDAD was identified at the 90th percentile of all infections. 'High CDAD' hospitals had on average ten times more CDAD cases than all other hospitals (Table 6). A comparison of the rates of bacterial pathogens and other common infections between 'high CDAD' hospitals and all other facilities (Table 6) revealed that the former were more likely to have *E. coli*, *Staphylococcus*, *Streptococcus*, and *Pseudomonas* infections (Table 6) and were also more likely to discharge patients with bloodstream infections, endocarditis, osteomyelitis, pneumonia, urinary tract infections, and cellulitis (Table 6). Hospitals in the 95th or 80th percentile of CDAD also showed similar associations.

'High CDAD' hospitals and hospital variables

A univariate analysis of hospital variables for 'high CDAD' hospitals (90th percentile of *C. difficile* infections) compared to others revealed that the former were less likely to provide neurology, orthopaedic, and palliative care services; in addition, they had fewer nurses and residents, performed fewer operations, discharged fewer patients and were characterized by slower bed turnover. Lastly, 'high CDAD' hospitals were not more likely to be classified as critical access facilities (Table 7).

State analysis

The median number of cases of CDAD cases was similar for California and Arizona and lowest for Minnesota. Despite the small difference in the median number of cases across the three states, the mean case rate (± s.d.) across states/1000 discharges were Arizona 11.1 ± 30.1 cases; California 6.5 ± 18.4 cases; Minnesota 2.9 ± 3.2 cases. In addition, the rate of CDAD among the hospitals in the 90th percentile of

Table 4. Bacterial correlations [correlation values (r) for individual pathogens in identified infections]

	<i>C. difficile</i>	<i>E. coli</i>	<i>Pseudomonas</i>	<i>Staphylococcus</i>	<i>Streptococcus</i>
<i>C. difficile</i>	1	0.188	0.762	0.692	0.575
<i>E. coli</i>		1	0.360	0.343	0.478
<i>Pseudomonas</i>			1	0.789	0.664
<i>Staphylococcus</i>				1	0.630
<i>Streptococcus</i>					1

Table 5. Infection correlations [correlation values (r) for common infections]

	<i>C. difficile</i>	Bloodstream	Cellulitis	Endocarditis	Osteomyelitis	Pneumonia	Urinary tract
<i>C. difficile</i>	1	0.683	0.452	0.626	0.610	0.584	0.570
Bloodstream		1	0.513	0.461	0.514	0.718	0.623
Cellulitis			1	0.400	0.560	0.587	0.652
Endocarditis				1	0.533	0.333	0.347
Osteomyelitis					1	0.405	0.432
Pneumonia						1	0.737
Urinary tract							1

Table 6. Hospital characteristics by CD colitis rate [differences in mean rates (\pm s.d.) of bacterial and infection characteristics between 'high CDAD' hospitals and all other facilities]

	'High CDAD' hospitals	All other hospitals	P value
Bacterial characteristics			
<i>C. difficile</i>	36.9 \pm 48.5	2.9 \pm 2.9	0.0001
<i>E. coli</i>	19.8 \pm 12.7	12.3 \pm 8.7	0.0001
<i>Pseudomonas</i>	16.2 \pm 23.5	3.3 \pm 3.5	0.0001
<i>Staphylococcus</i>	33.1 \pm 38.5	9.1 \pm 6.1	0.0001
<i>Streptococcus</i>	14.2 \pm 13.9	5.6 \pm 4.4	0.0001
Infection characteristics			
Bloodstream	70.6 \pm 93.3	19.8 \pm 13.1	0.0001
Cellulitis	46.1 \pm 31.1	25.4 \pm 14.3	0.0001
Endocarditis	3.0 \pm 5.2	0.8 \pm 0.9	0.0001
Osteomyelitis	16.5 \pm 2.7	4.1 \pm 4.8	0.0001
Pneumonia	184.1 \pm 146.0	82.8 \pm 49.2	0.0001
Urinary tract	142.7 \pm 94.7	64.0 \pm 33.0	0.0001

Values are mean rate/1000 discharges \pm s.d.

C. difficile cases was highest for Arizona (83.7 cases/1000 discharges), followed by California (36.5 cases), and lowest for Minnesota (10.3 cases).

Comparison of 'high CDAD' hospitals (in the 90th percentile) for each state revealed patterns similar to those in the complete cohort analysis described above. With few exceptions, there were significant correlations between CDAD rates and isolates of other pathogens as well as other common infections for hospitals in the state of California, Arizona, or Minnesota and results for individual hospital

reproduced those for the larger cohort. 'High CDAD' hospitals had fewer full-time registered nurses, fewer medical residents, fewer hospital beds, and performed fewer surgical procedures. There was also a significantly slower bed turnover (total discharges per bed) as found in the wider cohort analysis.

Multivariate analysis

Logistic regression analysis revealed that hospitals with transplant services [odds ratio (OR) 2.36, 95%

Table 7. Hospital characteristics by CD colitis rate (differences in hospital characteristics between 'high CDAD' hospitals and all other facilities)

	'High CDAD' hospitals	All other hospitals	P value
Hospital characteristic (proportion of hospitals with service line)			
Trauma hospital (%)	6.7	21.9	0.001
Critical access hospital (%)	15	11.2	n.s.
With patient burn beds (%)	2.1	3.4	n.s.
Haemodialysis services (%)	23.7	28.1	n.s.
Neurology services (%)	23.7	32.8	0.03
Orthopaedic services (%)	33.7	51.6	0.001
Palliative care services (%)	12.4	20.2	0.01
Transplant hospital (%)	8.5	7.2	n.s.
Emergency department services (%)	42.4	73.3	0.0001
Cardiac intensive care services (%)	26.1	36.6	0.01
Rehabilitation services (%)	18.0	24.1	n.s.
Hospital characteristic [number of staff, beds, discharges (mean \pm s.d.)]			
Full-time medical doctors	14.0 \pm 86.9	17.4 \pm 69.0	n.s.
Full-time registered nurses	112.4 \pm 170.5	159.3 \pm 199.2	0.0008
Full-time residents	4.7 \pm 43.4	17.0 \pm 68.8	0.01
Hospital beds	131.4 \pm 112.8	181.4 \pm 158.2	0.0001
Total surgical procedures	3396 \pm 4227.1	5441 \pm 5257.1	0.0001
Total yearly discharges	4298 \pm 5828.8	8713 \pm 8672.8	0.0001
Bed turnover (discharges/bed)	25.8 \pm 21.5	46.1 \pm 26.9	0.0001

confidence interval (CI) 1.15–4.93] were more likely to be in the 90th percentile of CDAD cases. Hospitals with emergency department services (OR 0.52, 95% CI 0.32–0.84) or trauma services (OR 0.29, 95% CI 0.13–0.62) were less likely to be in the 90th percentile and so were hospitals with faster bed turnover (OR 0.96, 95% CI 0.95–0.97). After adjusting for the above factors, the state in which the hospital was located and other AHA data variables were also not associated with high CDAD rates. Given that the majority of the latter hospitals were located in California and Arizona, a cohort of such hospitals was constructed for each state. A new cohort of hospitals that represented the 90th percentile of CDAD cases for each state was abstracted and the same multivariate analysis was conducted. This analysis revealed similar findings of increased risk of CDAD in hospitals with transplant services but decreased risk of CDAD in hospitals with emergency department services, trauma services, and faster bed turnover as well as an additional increased risk in hospitals providing haemodialysis services (OR 1.87, 95% CI 1.09–3.21).

DISCUSSION

This study examined hospital-level predictors of high rates of CDAD in over 2300 hospitals across California, Arizona, and Minnesota. The analysis of hospital characteristics is particularly useful, since most CDAD cases are acquired while patients are hospitalized [15]. Significant correlations between 'high CDAD' hospitals and facilities that admit large numbers of patients with other bacterial pathogens and other common infections was noted. In addition, although 'high CDAD' hospitals were more likely to provide transplant services, they were less likely to provide emergency department services or trauma services. The analysis by state revealed that the highest rates of CDAD occurred in Arizona; the lowest rates, in Minnesota. Thus, the present study revealed large variations in CDAD cases, with a clustering of common infections at 'high CDAD' hospitals.

Prior to this study, attempts to identify risk factors for CDAD have been conducted at the patient level. Pepin and colleagues found that older patients with multiple comorbidities were more likely to develop

CDAD [7] as were patients treated with proton pump inhibitors [28] or tube feedings [29]. Most have described an association between antibiotics, particularly the use of cephalosporins, clindamycin, or fluoroquinolones and CDAD [7, 30–34]. There were large differences in CDAD cases across hospitals, metropolitan statistical areas, and states. These differences are probably due to clustering of infections at particular facilities as was evident in the state analyses. State rates of CDAD demonstrated considerable difference between median and mean case rates and these were probably due to significant outbreaks of infection at particular types of facilities. This is further reinforced by the fact that ‘high CDAD’ hospitals had more than 10 times the number of CDAD cases than other hospitals while treating a significantly larger proportion of other common infections. Given this clustering of CDAD, it seems particularly important that prevention and control measures be applied in such high-risk hospitals. At this time a number of methods have been developed to reduce CDAD cases, including education, infection control measures (e.g. contact precautions or patient isolation), rigorous cleaning and disinfection protocols, and antibiotic restrictions [35, 36]. Although all hospitals should attempt to reduce outbreaks of CDAD, those with high numbers of other common infections are most in need of prevention and control measures.

In addition to hospital structural and personnel characteristics, the present study revealed that hospitals with high numbers of *Pseudomonas* and *Staphylococcus* infections were much more likely to diagnose and treat CDAD. ‘High CDAD’ hospitals also had high numbers of endocarditis and bloodstream infections which generally require prolonged hospital stay and antibiotic use, leading to a potentially higher CDAD risk. These findings are in agreement with the bed turnover ratio results, indicating that those facilities with a slower turnover of patients are at higher risk of CDAD. Hospitals with slower bed turnover rates and therefore increased CDAD rates may potentially have increased comorbidity or patient severity of illness. Others have described similar associations when comparing patient-level risk factors for CDAD [11–13].

The association between CDAD and other infections is probably due to the mechanism by which *C. difficile* causes disease, i.e. by reducing normal colonic flora with antibiotics used to treat another infection, followed by patients’ inoculation with

C. difficile spores [33, 34]. Despite the long-held view of CDAD pathophysiology, a recent systematic review investigated the association of antibiotics with CDAD in order to summarize the strength of the evidence for this relationship [37]. These researchers found that most studies demonstrate a correlation between CDAD and antibiotics, yet none were able to define a causal relationship. They concluded that well-designed studies grounded in epidemiological principles are needed to identify true risk factors for CDAD and to provide reliable estimates of the strength of the association [37]. Although we agree with those researchers, the analysis presented here of hospital-level risk factors provides alternative data regarding CDAD risk.

The present study has a number of strengths and limitations that are specific to the use of administrative data. Hospital in-patient discharge files do not provide clinical details commonly found in the medical record, such as culture results and treatment details. More information regarding culture results and treatment patterns would allow us to verify diagnostic codes while examining other associations. Despite the inability to confirm the presence of CDAD, others have used ICD-9 codes to evaluate trends in CDAD infections [2] while a recent study demonstrated 75% sensitivity for this diagnosis [38]. In addition, the identified variability in CDAD may have been influenced by the variable presence of infection control teams leading to detection bias for those ‘high CDAD’ hospitals [39]. These hospitals, however, had strikingly close correlations with other infections; thus, the data demonstrate reliable and significant correlations between ‘high CDAD’ hospitals and each of the infections queried in both the larger cohort and across the individual states. Thus, we were able to analyse risk factors that had not been previously studied in smaller single-institution studies. The strength of the study is grounded on the representative nature of a large cohort of hospitalized patients with CDAD in three states across different geographic regions of the United States.

In conclusion, the present study revealed high rates of CDAD in hospitals that discharge large numbers of patients with other bacterial pathogens and other common infections. The analysis revealed large differences in CDAD cases across metropolitan statistical areas and states and that ‘high CDAD’ hospitals were more likely to provide transplant services and have slower turnover of beds, reflecting longer hospital lengths of stay. These findings provide more

insight into the epidemiology of *C. difficile* and indicate marked differences in the burden of CDAD across localities.

ACKNOWLEDGEMENTS

The authors thank Franci Livingston for her assistance with the attainment of Minnesota hospital discharge data. The work is funded in part by a Minnesota Medical Foundation Grant.

DECLARATION OF INTEREST

None.

REFERENCES

- Ricciardi R, *et al.* Rising prevalence and severity of *Clostridium difficile* colitis in hospitalized patients in the United States. *Archives of Surgery* 2007; **142**: 624–631.
- McDonald LC, Owings M, Jernigan DB. *Clostridium difficile* infection in patients discharged from US short-stay hospitals, 1996–2003. *Emerging Infectious Diseases* 2006; **12**: 409–415.
- Loo VG, *et al.* A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. *New England Journal of Medicine* 2005; **353**: 2442–2449.
- Warny M, *et al.* Toxin production by an emerging strain of *Clostridium difficile* associated with outbreaks of severe disease in North America and Europe. *Lancet* 2005; **366**: 1079–1084.
- Pepin J, *et al.* Increasing risk of relapse after treatment of *Clostridium difficile* colitis in Quebec, Canada. *Clinical Infectious Diseases* 2005; **40**: 1591–1597.
- Musher DM, *et al.* Relatively poor outcome after treatment of *Clostridium difficile* colitis with metronidazole. *Clinical Infectious Diseases* 2005; **40**: 1586–1590.
- Pepin J, *et al.* Emergence of fluoroquinolones as the predominant risk factor for *Clostridium difficile*-associated diarrhea: a cohort study during an epidemic in Quebec. *Clinical Infectious Diseases* 2005; **41**: 1254–1260.
- Brbut F, Petit JC. Epidemiology of *Clostridium difficile*-associated infections. *Clinical Microbiology and Infection* 2001; **7**: 405–410.
- McFarland LV, *et al.* Nosocomial acquisition of *Clostridium difficile* infection. *New England Journal of Medicine* 1989; **320**: 204–210.
- Changela U, *et al.* Risk factors and mortality associated with *Clostridium difficile* associated diarrhoea at a VA hospital. *International Journal of Antimicrobial Agents* 2004; **24**: 562–566.
- Kyne L, *et al.* Underlying disease severity as a major risk factor for nosocomial *Clostridium difficile* diarrhea. *Infection Control and Hospital Epidemiology* 2002; **23**: 653–659.
- McFarland LV, Surawicz CM, Stamm WE. Risk factors for *Clostridium difficile* carriage and *C. difficile*-associated diarrhea in a cohort of hospitalized patients. *Journal of Infectious Diseases* 1990; **162**: 678–684.
- Brown E, *et al.* Risk factors for *Clostridium difficile* toxin-associated diarrhea. *Infection Control and Hospital Epidemiology* 1990; **11**: 283–290.
- Carling P, *et al.* Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. *Infection Control and Hospital Epidemiology* 2003; **24**: 699–706.
- Noren T, *et al.* Molecular epidemiology of hospital-associated and community-associated *Clostridium difficile* infection in a Swedish county. *Journal of Clinical Microbiology* 2004; **42**: 3635–3643.
- Health Forum. American Hospital Association: Hospital Connect Online Store (https://www.associationstores.org/OA_HTML/ibeCCtpItdspRte.jsp?section=10352&item=207). Accessed 8 November 2005.
- Elting LS, *et al.* Correlation between annual volume of cystectomy, professional staffing, and outcomes: a statewide, population-based study. *Cancer* 2005; **104**: 975–984.
- Powner DJ, Hernandez M, Rives TE. Variability among hospital policies for determining brain death in adults. *Critical Care Medicine* 2004; **32**: 1284–1288.
- Irvin CB, Fox JM, Pothoven K. Financial impact on emergency physicians for nonreimbursed care for the uninsured. *Annals of Emergency Medicine* 2003; **42**: 571–576.
- Aronsky D, *et al.* Accuracy of administrative data for identifying patients with pneumonia. *American Journal of Medical Quality* 2005; **20**: 319–328.
- Taub DA, *et al.* Complications following surgical intervention for stress urinary incontinence: A national perspective. *Neurourology and Urodynamics* 2005; **24**: 659–665.
- Abbott KC, *et al.* Hospitalizations for bacterial endocarditis after renal transplantation in the United States. *Journal of Nephrology* 2001; **14**: 353–360.
- Ellis Simonsen SM, *et al.* Cellulitis incidence in a defined population. *Epidemiology and Infection* 2006; **134**: 293–299.
- Dombrovskiy VY, *et al.* Facing the challenge: Decreasing case fatality rates in severe sepsis despite increasing hospitalizations. *Critical Care Medicine* 2005; **33**: 2555–2562.
- Upchurch PK, *et al.* Osteomyelitis of the foot and toe in adults is a surgical disease. *Annals of Surgery* 2005; **241**: 885–894.
- Morris AM, *et al.* *Clostridium difficile* colitis. An increasingly aggressive iatrogenic disease? *Archives of Surgery* 2002; **137**: 1096–1100.
- Dallal RM, *et al.* Fulminant *Clostridium difficile*: an underappreciated and increasing cause of death and complications. *Annals of Surgery* 2002; **235**: 363–372.
- Dial S, *et al.* Risk of *Clostridium difficile* diarrhea among hospital inpatients prescribed proton pump

- inhibitors: cohort and case-control studies. *Canadian Medical Association Journal* 2004; **171**: 33–38.
29. **Bliss DZ, et al.** Acquisition of *Clostridium difficile*-associated diarrhea in hospitalized patients receiving tube feeding. *Annals of Internal Medicine* 1998; **129**: 1012–1019.
 30. **Aronsson B, Mollby R, Nord CE.** Antimicrobial agents and *Clostridium difficile* in acute enteric disease: epidemiological data from Sweden, 1980–1982. *Journal of Infectious Diseases* 1985; **151**: 476–481.
 31. **Bartlett JG.** Antibiotic-associated diarrhea. *Clinical Infectious Diseases* 1992; **15**: 573–581.
 32. **Spencer RC.** The role of antimicrobial agents in the aetiology of *Clostridium difficile* associated disease. *Journal of Antimicrobial Chemotherapy* 1998; **41** (Suppl. C): 21–27.
 33. **Gurwith MJ, Rabin HR, Love K.** Diarrhea associated with clindamycin and ampicillin therapy: preliminary results of a cooperative study. *Journal of Infectious Diseases* 1977; **135S**: S104–110.
 34. **Pear SM, et al.** Decrease in nosocomial *Clostridium difficile*-associated diarrhea by restricting clindamycin use. *Annals of Internal Medicine* 1994; **120**: 272–277.
 35. **Cartmill TD, et al.** Management and control of a large outbreak of diarrhoea due to *Clostridium difficile*. *Journal of Hospital Infection* 1994; **27**: 1–15.
 36. **Tedesco FJ, Barton RW, Alpers DH.** Clindamycin-associated colitis. A prospective study. *Annals of Internal Medicine* 1974; **81**: 429.
 37. **Thomas C, Stevenson M, Riley TV.** Antibiotics and hospital-acquired *Clostridium difficile*-associated diarrhoea: a systematic review. *Journal of Antimicrobial Chemotherapy* 2003; **51**: 1339–1350.
 38. **Dubberke ER, et al.** ICD-9 codes and surveillance for *Clostridium difficile*-associated disease. *Emerging Infectious Diseases* 2006; **12**: 1576–1579.
 39. **Zoutman D, Ford BD.** The relationship between hospital infection surveillance and control activities and antibiotic-resistant pathogen rates. *American Journal of Infection Control* 2005; **33**: 1–5.